Latest news and press releases about Barinthus Biotherapeutics plc (BRNS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease.
Price
| Price | $0.74 |
| Market Cap | $30M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.53 |
| EV / EBITDA | 0.48 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -59.18% |
| Return on Invested Capital | -61.15% |
| Return on Assets | -50.97% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · CVM · INMB · KPTI · KZR · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of BRNS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks